NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, Porter JR, Shair MD, Zhu VW, Felip E, Cho BC, Friboulet L, Hata AN, Pelish HE, Drilon A.
Lin JJ, et al. Among authors: nguyen phuong l.
Cancer Discov. 2024 Dec 2;14(12):2367-2386. doi: 10.1158/2159-8290.CD-24-0231.
Cancer Discov. 2024.
PMID: 39269178
Free PMC article.
Clinical Trial.